A practical reference on Anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-06 and is reviewed periodically as new material appears.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
== Epidemiology == Gynecomastia is the most common benign disorder of the male breast tissue and affects 35 percent of men, being most prevalent between the ages of 50 and 69. New cases of gynecomastia are common in three age populations: newborns, adolescents, and men older than 50 years. Newborn gynecomastia occurs in about 60–90 percent of male babies, and most cases resolve on their own in about 2–3 weeks after delivery. During adolescence, on average, 33 percent of males are estimated to exhibit signs of gynecomastia. Gynecomastia in older men is estimated to be present in 24–65 percent of men between the ages of 50 and 80. Estimates on asymptomatic gynecomastia are about up to 70% in men aged 50 to 69 years. The prevalence of gynecomastia in men may have increased in recent years, but the epidemiology of the disorder is not fully understood. The use of anabolic steroids and exposure to chemicals that mimic estrogen in cosmetic products, organochlorine pesticides, and industrial chemicals have been suggested as possible factors driving this increase. According to the American Society of Plastic Surgeons, breast reduction surgeries to correct gynecomastia are fairly common but has been a recent decline. In 2020, there were over 18,000 procedures of this type performed in the United States, which is down 11% from 2019.
In nuclear engineering, a delayed neutron is a neutron released not immediately during a nuclear fission event, but shortly afterward—ranging from milliseconds to several minutes later. These neutrons are emitted by excited daughter nuclei of certain beta-decaying fission products. In contrast, prompt neutrons are emitted almost instantaneously—within about 10−14 seconds—at the moment of fission. During fission, a heavy nucleus splits into two smaller, neutron-rich fragments (fission products), releasing several free neutrons known as prompt neutrons. Many of these fission products are radioactive and typically undergo beta decay to reach more stable configurations. In a small subset of cases, the beta decay of a fission product results in a daughter nucleus in an excited state with enough energy to emit a neutron. This neutron, emitted shortly after fission but delayed due to the beta decay process, is called a delayed neutron. The delay in neutron emission arises from the time required for the precursor nuclide (the beta-decaying fission product) to undergo beta decay—a process that takes orders of magnitude longer than the prompt emission of neutrons during fission. While the delayed neutron is emitted almost immediately after beta decay, it is actually released by the excited daughter nucleus produced in that decay. Therefore, the overall timing of delayed neutron emission is governed by the beta decay half-life of the precursor. Delayed neutrons are critically important for controlling nuclear reactors.
== Selected publications == Drucker, D. J.; Philippe, J; Mojsov, S; Chick, W. L.; Habener, J. F. (1987). "Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line". Proceedings of the National Academy of Sciences of the United States of America. 84 (10): 3434–8. Bibcode:1987PNAS...84.3434D. doi:10.1073/pnas.84.10.3434. PMC 304885. PMID 3033647. Scrocchi, L.S.; Brown, T.J.; Maclusky, N.; Brubaker, P.L.; Auerbach, A.B.; Joyner, A.L.; Drucker, D.J. (1996). "Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene". Nature Medicine. 2 (11): 1254–1258. doi:10.1038/nm1196-1254. PMID 8898756. Drucker, D.J.; Ehrlich, P.; Asa, S. L.; Brubaker, P.L. (1996). "Induction of intestinal epithelial proliferation by glucagon-like peptide 2". Proc Natl Acad Sci U S A. 93 (15): 7911–7916. Bibcode:1996PNAS...93.7911D. doi:10.1073/pnas.93.15.7911. PMC 38848. PMID 38848. Chen, E.; Drucker, D.J. (1997). "Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard". Journal of Biological Chemistry. 272 (7): 4108–15. doi:10.1074/jbc.272.7.4108. PMID 9020121. Drucker, D.J.; Shi, Q.; Crivici, A.; Sumner-Smith, M.; Tavares, W.; Hill, M.; DeForest, L.; Cooper, S.; Brubaker, P.L. (1997). "Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV". Nature Biotechnology. 93 (15): 7911–6. doi:10.1038/nbt0797-673. PMID 9219272.
lipid Any of a heterogeneous class of organic compounds, including glycerides (fats), waxes, sterols, and some vitamins, united only by their amphipathic or hydrophobic nature and consequently their very low solubility in water. Some lipids such as phospholipids tend to form lamellar structures or micelles in aqueous environments, where they serve as the primary constituents of biological membranes. Others such as fatty acids can be metabolized for energy, have important functions in energy storage, or serve as signaling molecules. Colloquially, the term "lipids" is sometimes used as a synonym for fats, though fats are more correctly considered a subclass of lipids.
Sources: en.wikipedia.org
Though it is owned by the New York City Department of Parks and Recreation, Bryant Park is managed by the private not-for-profit organization Bryant Park Corporation, which was founded in 1980 and led the restoration of Bryant Park. The park is cited as a model for the success of public-private partnerships. The park is both a National Register of Historic Places listing and a New York City designated landmark.
Asian citrus psyllid on the UF / IFAS Featured Creatures Web site Species Profile – Citrus Greening and Species Profile – Asian Citrus Psyllid, National Invasive Species Information Center, National Agricultural Library. Lists general information and resources for citrus greening and the Asian citrus psyllid. CISR: Huanglongbing/Citrus Greening Center for Invasive Species Research page on Huanglongbing and Citrus Greening
=== Power differential DSC === For this kind of setup, also known as Power compensating DSC, the sample and reference crucible are placed in thermally insulated furnaces and not next to each other in the same furnace as in heat-flux-DSC experiments. Then the temperature of both chambers is controlled so that the same temperature is always present on both sides. The electrical power that is required to obtain and maintain this state is then recorded rather than the temperature difference between the two crucibles.
Sources: en.wikipedia.org
A broader survey of Drosophila de novo proteins likewise found that most differ from conserved proteins in predicted properties, but that a subset are predicted to adopt known folds and participate in specific cellular processes. Inference from prediction tools requires caution because many predictors were trained and benchmarked primarily on conserved, globular proteins, and their performance can be biased for short or low-homology sequences. In particular, disorder predictions can be sensitive to parameter choices, and different structure predictors (including alignment-based and protein language model approaches) may disagree on de novo proteins and yield low-confidence models. Comparisons of "newly born" orphan proteins to "never born" random polypeptides using multiple deep-learning structure predictors similarly reported that predicted models are often of low quality while still allowing limited qualitative comparisons across sequence sets.
=== Rodbell's Department Store === Bonnie Watkins (Bonnie Bramlett, credited as Bonnie Sheridan) – Roseanne's coworker at Rodbell's, during season three and four. She has a daughter who lives in Oregon and enjoys traveling by motorcycle with her husband Duke (David Crosby). Bonnie had a drinking problem along with her husband Duke early on in her life that she has since brought under control.
Aceclidine is a parasympathomimetic cholinergic drug that functions as a muscarinic acetylcholine receptor agonist. It is used in ophthalmology as a miotic agent to constrict the pupil. Historically used in Europe for the treatment of glaucoma, aceclidine received its first U.S. approval in 2025 under the brand name Vizz as a topical eye drop for the correction of presbyopia. Its mechanism of action produces pupil contraction with a relatively minimal effect on the ciliary muscle, which improves near visual acuity through a "pinhole" depth-of-field effect without inducing significant accommodative spasm.
As an expression of gratitude for New Zealand's hospitality, he and others arranged a free event, We Love Aotearoa, with live performances from musicians across New Zealand. It was accompanied by VR stands for Valve games such as Half-Life: Alyx and The Lab. The event was postponed from August to December due to a lockdown induced by a second wave of COVID-19. Newell applied for permanent residency in New Zealand in October 2020, but had returned to Seattle by 2021. Since the 1990s, Newell has owned and sold several homes in Seattle, including a home in Capitol Hill, two homes on Lake Washington and a holiday home in Long Beach Peninsula. He owns several ships and has lived mostly at sea since the pandemic. In June 2026, he purchased a 20,000-square-foot mansion in Florida for $70.8 million, with 7 bedrooms, 13 bathrooms, an 8-car garage, an outdoor pool, a dock, a boat lift, an elevator, and a private tunnel to a beach. As of 2026, Newell had lost a substantial amount of weight.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.